source
- From confidence to capital: Positioning biotech for the next growth cycleHow can biotechs be investor ready? Key takeaways from BIO International and DIA China 2026.
- MapLight’s schizophrenia drug dampens once-daily hopes despite Phase 2 winMapLight Therapeutics’ stock {$MPLT} plummeted more than 60% on Monday after a once-daily regimen of its schizophrenia drug missed the primary endpoint in a mid-stage trial, despite the study’s ove…